Last reviewed · How we verify
Alimta or Taxotere
At a glance
| Generic name | Alimta or Taxotere |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
- Anemia
- Neutrophil count decreased
- Fatigue
- Creatinine increased
- Nausea
- Constipation
- Diarrhoea
- Asthenia
- Cough
- Dyspnoea
- Decreased Appetite
- Vomiting
Key clinical trials
- Study of Novel Treatment Combinations in Patients With Lung Cancer (PHASE2)
- SYS6090 Combination Therapy in Advanced Lung Cancer (PHASE1, PHASE2)
- AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer (PHASE1, PHASE2)
- A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (PHASE2, PHASE3)
- Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer (PHASE3)
- A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC (PHASE2)
- A Study of ASP3082 in Adults With Advanced Solid Tumors (PHASE1)
- A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Alimta or Taxotere CI brief — competitive landscape report
- Alimta or Taxotere updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI